Biomarkers of Immune-Related Toxicity
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 95
Summary
- Conditions
- Cancer
- Metastatic Cancer
- Type
- Observational
- Design
- Observational Model: Case-ControlTime Perspective: Cross-Sectional
Participation Requirements
- Age
- Between 18 years and 100 years
- Gender
- Both males and females
Description
This is a single-center, correlative pilot study evaluating potential biomarkers predictive of immune-related adverse events associated with immune checkpoint inhibitor therapy. The study includes a control population of patients receiving standard chemotherapy as a comparator. Patients will undergo...
This is a single-center, correlative pilot study evaluating potential biomarkers predictive of immune-related adverse events associated with immune checkpoint inhibitor therapy. The study includes a control population of patients receiving standard chemotherapy as a comparator. Patients will undergo blood draws at 4 time-points while on standard of care treatment. There are no study-related medications or interventions beyond blood sampling.
Tracking Information
- NCT #
- NCT03409016
- Collaborators
- Cancer League of Colorado
- Investigators
- Principal Investigator: Sarah L Davis, MD University of Colorado, Denver
Get Well Soon